2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3081

IRF5 Deletion Prevents the SLE-like Disease Initiated By Dendritic Cell-Specific Loss of Caspase 8
Abstract Number: 3082

Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice
Abstract Number: 3083

Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus
Abstract Number: 3084

Progression of Lupus Pathology Is Correlative with Cardiac Magnetic Resonance Imaging Abnormalities, Diminished Function, and Inflammatory Histopathology in an Animal Model
Abstract Number: 3085

Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus
Abstract Number: 3086

The Same Multidimensional Patient Health Assessment Questionnaire Used to Assess RAPID3 in Rheumatoid Arthritis, Osteoarthritis and Other Rheumatic Diseases Can Provide Quantitative Clues to Recognize and Document Comorbid Fibromyalgia
Abstract Number: 3087

Cell Bound Complement Activation Products in Multianalyte Assay with Algorithm Have Utility in Distinguishing Primary Fibromyalgia from Systemic Lupus Erythematosus
Abstract Number: 3088

Genome Wide Expression Analyses Reveal Potentially Novel Drug Targets in Fibromyalgia
Abstract Number: 3089

Evaluation of Learned Helplessness, Perceived Self-Efficacy and Functional Capacity in Patients with Fibromyalgia and Rheumatoid Arthritis
Abstract Number: 3090

Fibromyalgia Predicts Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients
Abstract Number: 3091

A Randomized, Controlled Trial of Pregabalin in Adolescent Patients (12-17 years) with Fibromyalgia
Abstract Number: 3092

Deficiency of Adenosine Deaminase Type II – Expanding the Clinical Spectrum
Abstract Number: 3093

Development and Validation of Diagnostic Criteria for Cryopyrin Associated Periodic Syndromes
Abstract Number: 3094

Dose Adjustment of Anakinra (Kineret®) Based on Clinical Response in Patients with Severe Cryopyrin-Associated Periodic Syndromes
Abstract Number: 3095

Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].